Literature DB >> 17266388

Preferred drug lists and Medicaid prescriptions.

Tamer Abdelgawad1, Lisa Egbuonu-Davis.   

Abstract

BACKGROUND: When Medicaid preferred drug lists (PDLs) are implemented, they may impose indirect costs on prescribing physicians and Medicaid patients, leading to an unintended reduction in the number of Medicaid prescriptions filled.
OBJECTIVE: To test retrospectively the proposition that PDLs adversely affect the number of Medicaid prescriptions filled. DATA AND METHODS: We compared three 'test' states (Alabama, Texas, and Virginia) that implemented PDLs with restrictions on the prescription of statins with three 'control' states (New Jersey, North Carolina, and Pennsylvania) that did not implement drug access restrictions. We conducted the analysis at the county level and used a differences-in-differences approach that allows for county and time-period fixed effects.
RESULTS: We found that PDLs adversely impacted several measures of filled Medicaid prescriptions in the 'test' states relative to the 'control' states.
CONCLUSION: There are unintended but potentially harmful consequences to cost-focused health policy interventions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17266388     DOI: 10.2165/00019053-200624003-00005

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  4 in total

1.  Pharmaceuticals: pharmaceutical cost controls--2005. End of Year Issue Brief.

Authors:  Melicia Seay; Priya Varma
Journal:  Issue Brief Health Policy Track Serv       Date:  2005-12-31

2.  Exploration of the impact of preferred drug lists on hospital and physician visits and the costs to Medicaid.

Authors:  Matthew M Murawski; Tamer Abdelgawad
Journal:  Am J Manag Care       Date:  2005-01       Impact factor: 2.229

3.  The role of health insurance coverage in reducing racial/ethnic disparities in health care.

Authors:  Marsha Lillie-Blanton; Catherine Hoffman
Journal:  Health Aff (Millwood)       Date:  2005 Mar-Apr       Impact factor: 6.301

4.  Benefits and risks of increasing restrictions on access to costly drugs in Medicaid.

Authors:  Stephen B Soumerai
Journal:  Health Aff (Millwood)       Date:  2004 Jan-Feb       Impact factor: 6.301

  4 in total
  2 in total

1.  Medicaid preferred drug lists: cost containment and side effects.

Authors:  Alvin E Headen
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

2.  Medicaid prescription formulary restrictions and arthritis treatment costs.

Authors:  Tricia J Johnson; Stephanie Stahl-Moncada
Journal:  Am J Public Health       Date:  2008-05-29       Impact factor: 9.308

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.